MGMT and central nervous system cancer: Although hereditary DNA repair defects (involving the BRCA genes) have not been described to play a role in gliomas, downregulation or pharmacologic inhibition of HR or PARP-1 may be a reasonable strategy, notably for MGMT-expressing tumors.